# Landiolol in Mitral Valve Surgery

Study · id `cardio:ct-nct06793670` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06793670](<https://clinicaltrials.gov/study/NCT06793670>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06793670

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1500 participants.

## Technical summary

Registry record NCT06793670. Randomized; double masking; primary purpose prevention. Start 2025-01-28 (actual); primary completion 2027-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 1500 participants (planned count; ClinicalTrials.gov record NCT06793670, source copy `cardio:ctgov-nct06793670-2025-12-29`, retrieved 2026-10-26)
- Started: 2025-01-28 (actual) (ClinicalTrials.gov record NCT06793670, source copy `cardio:ctgov-nct06793670-2025-12-29`, retrieved 2026-10-26)
- Primary completion: 2027-06 (anticipated) (ClinicalTrials.gov record NCT06793670, source copy `cardio:ctgov-nct06793670-2025-12-29`, retrieved 2026-10-26)
- Completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT06793670, source copy `cardio:ctgov-nct06793670-2025-12-29`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT06793670, source copy `cardio:ctgov-nct06793670-2025-12-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06793670-2025-12-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Landiolol in Mitral Valve Surgery
- Acronym: LUNA
- Condition: Cardiac Failure
- Condition: Low Cardiac Output Syndrome
- Intervention (Drug): Landiolol
- Intervention (Drug): Placebo
- Lead sponsor: Università Vita-Salute San Raffaele
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

## Provenance

Content hash: 7ed623549f90c22e87edfd79e235a02e13329a91a6bf640d3b06597993ac78da
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
